Pancreatic Cancer
Pancreatic Carcinoma
Female, 35 years
Patient Internal ID: 565420126
ICD-10 code
C25.8 Malignant Neoplasm: Overlapping Lesion of Pancreas
Diagnosis (Incl. Metastases/Stage) and Year
November 2017
Pancreatic Carcinoma pT3N1M0 G1 L/V1 R0 Stage III. Disease progression in June 2019, Metastasis to Small Bowel Mesentery and Abdominal Lymph Nodes, suspected Lung Metastases. Disease progression in the Small Bowel
Previous Treatment
Surgery, Chemotherapy (FOLFIRINOX), Chemotherapy (Capecitabine + Gemcitabine).
Prognosis and Survival Expectation
The prognosis remains very poor, the median overall survival of Pancreatic Cancer is ~9 months from diagnosis. 5-year relative survival rate for distant spread Pancreatic Cancer is 3%.
Treatment Provided
Autologous CIK (4 doses) over a period of 3 months. Additionally, the patient received Umbilical Cord Blood Derived NK cells (7 doses).
Patient Survival/Condition and Year
Date of Review: 30/01/2024
The patient has survived for 39 months since the diagnosis and 20 months since disease progression. It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended patient survival by an estimate of around 30 months.
